The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1071
February 7, 2000
View Complete Issue         Table of Contents 2019 
Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer
February 7, 2000 (Issue: 1071)
Epirubicin, an analog of doxorubicin that has been available in Europe and Canada for 15 years, has now been approved by the FDA for adjuvant use after resection of the primary tumor in breast cancer patients with axillary node involvement.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Epirubicin for Adjuvant Therapy in Node-Positive Breast Cancer
Article code: 1071b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.